Source:http://linkedlifedata.com/resource/pubmed/id/12499621
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
2002-12-24
|
| pubmed:abstractText |
This study was performed to evaluate whether thallium-201 myocardial scintigraphy (Tl-201) and iodine-123-metaiodobenzylguanidine (MIBG) myocardial scintigraphy could predict the usefulness of beta-blocker therapy in patients with dilated cardiomyopathy (DCM). Tl-201 and MIBG were performed in 47 patients before beta-blocker therapy. Patients were classified into group A, if their cardiac function improved, and group B, whose function remained unchanged. Two types of extent score (ES) by Tl-201 were proposed to quantitate myocardial damage, mean-2SD (ES-2) and mean-3SD (ES-3). The ES difference between ES-2 and ES-3 was calculated, and according to ES and ES difference, DCM cases were classified into 3 groups: mild-defect type (mild-type), moderate-defect type (moderate-type) and severe-defect type (severe-type). The heart-to-mediastinum (H/M) MIBG uptake ratio was evaluated, and the percent washout ratio of myocardial MIBG was obtained from these data. Group A comprised 18 mild-type, 14 moderate-type and 1 severe-type cases, and group B comprised 5 mild-type, 4 moderate-type and 5 severe-type cases. A significant relation was observed between the defect type on Tl-201 and the response to beta-blocker therapy (p=0.0090). Both H/M MIBG uptake ratios and washout ratio were not significantly different in the 2 groups. Tl-201 may be useful for predicting the response to beta-blocker therapy in patients with DCM.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/3-Iodobenzylguanidine,
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic beta-Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Carbazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Metoprolol,
http://linkedlifedata.com/resource/pubmed/chemical/Propanolamines,
http://linkedlifedata.com/resource/pubmed/chemical/Radiopharmaceuticals,
http://linkedlifedata.com/resource/pubmed/chemical/Thallium Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/bevantolol,
http://linkedlifedata.com/resource/pubmed/chemical/carvedilol
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1346-9843
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
66
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1139-43
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:12499621-3-Iodobenzylguanidine,
pubmed-meshheading:12499621-Adrenergic beta-Antagonists,
pubmed-meshheading:12499621-Adult,
pubmed-meshheading:12499621-Aged,
pubmed-meshheading:12499621-Carbazoles,
pubmed-meshheading:12499621-Cardiomyopathy, Dilated,
pubmed-meshheading:12499621-Female,
pubmed-meshheading:12499621-Forecasting,
pubmed-meshheading:12499621-Heart,
pubmed-meshheading:12499621-Hemodynamics,
pubmed-meshheading:12499621-Humans,
pubmed-meshheading:12499621-Male,
pubmed-meshheading:12499621-Metoprolol,
pubmed-meshheading:12499621-Middle Aged,
pubmed-meshheading:12499621-Multivariate Analysis,
pubmed-meshheading:12499621-Probability,
pubmed-meshheading:12499621-Propanolamines,
pubmed-meshheading:12499621-Radiopharmaceuticals,
pubmed-meshheading:12499621-Thallium Radioisotopes,
pubmed-meshheading:12499621-Treatment Outcome
|
| pubmed:year |
2002
|
| pubmed:articleTitle |
Use of thallium-201 myocardial scintigraphy for the prediction of the response to beta-blocker therapy in patients with dilated cardiomyopathy.
|
| pubmed:affiliation |
The Second Department of Internal Medicine, Ehime University School of Medicine, Japan. yujihara@m.ehime-u.ac.jp
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial
|